CN110272990A - Excretion body microRNA is as depression marker and its application - Google Patents
Excretion body microRNA is as depression marker and its application Download PDFInfo
- Publication number
- CN110272990A CN110272990A CN201910567173.4A CN201910567173A CN110272990A CN 110272990 A CN110272990 A CN 110272990A CN 201910567173 A CN201910567173 A CN 201910567173A CN 110272990 A CN110272990 A CN 110272990A
- Authority
- CN
- China
- Prior art keywords
- hsa
- mir
- expression
- test individual
- increases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The present invention provides excretion body microRNA as depression marker and its application.Specifically, the present invention provides the reagent materials of microRNA level in sample of the detection from test individual and/or instrument and equipment to prepare the application in the detection system for diagnosing depression risk.Excretion body microRNA of the invention can be used as the biomarker of diagnosis depressive patients.
Description
Technical field
The present invention relates to it is a kind of diagnose depressive patient biomarker and related application, specifically, be about
Using excretion body microRNA as the technology of diagnosis depression suspected patient, belong to biology and medicine technology field.
Background technique
Major depressive disorder (MDD) is also known as depressive disorder, is one of most common mental disorder in the whole world, with significant
Low lasting mental state is main clinic symptoms, is the main Types of mood disorder.Clinical visible mental state it is low with its situation not
Match, the downhearted of mood can be from depressed to extremely grieved or even pessimistic and worldweary, there is conamen or behavior；Part disease
Example has apparent anxiety and motility radical；Serious person may occur in which the psychotic symptoms such as illusion, vain hope.Every time breaking-out continue to
2 weeks or more few, some duration are up to the several years, and most of cases have the tendency that recurrent exerbation, with h and E
Equal many factors are related, influence 3.5 hundred million people of the whole world now.
There are two types of common first generation antidepressants, i.e. monoamine oxidase inhibitors (MAOI) and tricyclic antidepressant
(TCA), however the side effect of all these antidepressants and therapeutic effect still have dispute, it is most important the reason is that due to
The mechanism of MDD, which is not studied, to be defined, it is a kind of complex disease that the cause of disease is different, and the cell and molecular basis of this disease be not also clear
It is clear.In the past few decades, many researchs all concentrate on monoamine hypothesis, it is believed that norepinephrine, dopamine and serum
Element plays an important role in the pathogenesis of depression, however bad for the effect of drugs of monoamine reuptaking inhibitor, and 2/3
Patient not up to alleviate after a course for the treatment of, 1/3 patient fails to alleviate after 4 treatments.Therefore, new have to develop
Imitate treatment method, it is necessary to more be studied the cause of disease of MDD, to determine the biomarker of disease.
Excretion body, a kind of volume of the various kinds of cell release by including neuron and spongiocyte are 40-100nm's
Vesicles, due to its content carry the protein of specificity, lipid and functional mRNA, ncRNA (lncRNA,
MicroRNA, siRNA) etc. bioactive substances, and participate in cell communication, cell migration, angiogenesis promoting and anti-in vivo
The physiology courses such as tumour immunity, play an important role in the nervous system disease, have been to be concerned by more and more people.Due to
The special construction and function of excretion body, so that it has potential application, therefore in the excretion body for passing through serum origin
MiR-139-5p diagnoses MDD, can effectively assist uncertain human factor in Current Diagnostic, reduces misdiagnosis rate, should
Marker has good sensitivity and specificity with good.
Currently, clinically to the diagnosis of MDD mainly according to the detailed history and mental symptom of patient, by HAMD and
The subjective scorings such as MADRS scale do comprehensive descision, and since the subjective experience of doctor is different, there is also differences diagnostic result.For
Keep the diagnosis of MDD more objective, reduces human factor, improve the consistency and accuracy of diagnosis, in recent years all over the world
Researcher has been devoted to find the biomarker of MDD, establishes effective detection method.
Summary of the invention
An object of the present invention is to provide a kind of new depression biomarker.
Another object of the present invention is to provide the related applications of the depression biomarker.
Inventor is extracted excretion body and total serum IgE from subject's peripheral blood, sample is carried out in a research
Full microRNA sequencing analysis, and gene expression abundance is for statistical analysis.In analysis, screened for the expression quantity of 33 samples
The miRNA of 38 expression significant differences between Healthy People and patients with depression out.In further research, to data carry out with
Machine forest algorithm model training filters out miRNA marker (hsa-miR-181a-2-3p, hsa-miR-139-5p, hsa-
miR-942-5p、hsa-miR-4497、hsa-miR-421、hsa-miR-641、hsa-miR-22-5p、hsa-miR-331-5p、
hsa-miR-517a-3p、hsa-miR-532-5p、hsa-miR-425-5p、hsa-miR-151a-5p、hsa-let-7a-3p、
hsa-miR-151b、hsa-miR-191-5p、hsa-miR-126-3p、hsa-miR-484、hsa-miR-1304-5p、hsa-
miR-340-3p、hsa-miR-185-3p、hsa-miR-27a-5p、hsa-miR-330-5p、hsa-miR-338-5p、hsa-
MiR-361-5p, hsa-miR-100-5p) classifier is established, AUC index is up to 96.64%, sensibility and specificity difference
For 96.97% and 84.78%.
Combination variance Analysis and Screening and random forests algorithm model discrimination, thus, on the one hand, the present invention provides with next
The application of kind or a variety of microRNA as the biomarker of diagnosis depression:
hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-
641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-
5p、hsa-miR-4497、hsa-miR-495-3p、hsa-miR-100-5p、hsa-miR-511-5p、hsa-miR-421、hsa-
miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-378c、hsa-miR-769-5p、hsa-
miR-19a-3p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let-
7b-3p、hsa-miR-127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、
hsa-miR-32-5p、hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR-
3656、hsa-miR-1268a。
On the other hand, the present invention also provides the reagent materials of microRNA level in sample of the detection from test individual
And/or instrument and equipment includes preparing the application in detection system for diagnosing depression risk, the microRNA
The combination of one or more of:
hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-
641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-
5p、hsa-miR-4497、hsa-miR-495-3p、hsa-miR-100-5p、hsa-miR-511-5p、hsa-miR-421、hsa-
miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-378c、hsa-miR-769-5p、hsa-
miR-19a-3p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let-
7b-3p、hsa-miR-127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、
hsa-miR-32-5p、hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR-
3656、hsa-miR-1268a。
Specific embodiment according to the present invention, the present invention in, microRNA level includes peripheral blood expression, one
It is peripheral blood serum expression in more particular embodiment.
Specific embodiment according to the present invention, the present invention in, hsa-miR-139-5p, hsa-miR-340- detected
3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、
hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、hsa-miR-495-3p、hsa-miR-511-5p、
hsa-miR-421、hsa-miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-19a-3p、hsa-
miR-335-3p、hsa-miR-625-3p、hsa-let-7b-3p、hsa-miR-204-5p、hsa-miR-494-3p、hsa-
The expression of miR-32-5p, hsa-miR-96-5p increase, and test individual depression risk increases.
Specific embodiment according to the present invention, the present invention in, hsa-miR-139-5p, hsa-miR-340- detected
3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、
hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、hsa-miR-495-3p、hsa-miR-511-5p、
The expression of hsa-miR-421, hsa-miR-361-5p, hsa-miR-1304-5p increase, test individual depression illness wind
Danger increases.
Specific embodiment according to the present invention, the present invention in, hsa-miR-139-5p, hsa-miR-340- detected
3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、
The expression of hsa-miR-126-3p, hsa-miR-330-5p, hsa-miR-22-5p increase, test individual depression illness
Risk increases.
Specific embodiment according to the present invention, the present invention in, hsa-miR-4497, hsa-miR-100- detected
5p、hsa-miR-378c、hsa-miR-769-5p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-127-5p、hsa-
miR-4488、hsa-miR-7704、hsa-miR-17-3p、hsa-miR-378d、hsa-miR-184、hsa-miR-3656、
The expression of hsa-miR-1268a reduces, and test individual depression risk increases.
Specific embodiment according to the present invention, the present invention in, hsa-miR-4497, hsa-miR-100- detected
5p、hsa-miR-378c、hsa-miR-769-5p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-127-5p、hsa-
The expression of miR-4488, hsa-miR-7704, hsa-miR-17-3p reduce, and test individual depression risk increases.
Specific embodiment according to the present invention, the present invention in, hsa-miR-4497, hsa-miR-100-5p detected
Expression reduce, test individual depression risk increase.
On the other hand, the present invention also provides a kind of detection systems for assessing depression risk comprising: detection comes from
The reagent material and/or instrument and equipment of one or more of microRNA level in the sample of test individual:
hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-
641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-
5p、hsa-miR-4497、hsa-miR-100-5p、hsa-miR-378c、hsa-miR-769-5p、hsa-miR-19a-3p、
hsa-miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let-7b-3p、hsa-
miR-127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、hsa-miR-
32-5p、hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR-3656、hsa-
miR-1268a。
Specific embodiment according to the present invention, the detection system of assessment depression risk of the invention comprising:
Detection unit, the detection unit include detecting the reagent material and/or instrument and equipment of the microRNA level；
Analytical unit, the analytical unit is for analyzing the testing result of detection unit, assessment test individual depression
Disease risk.
Specific embodiment according to the present invention, it is described in the detection system of assessment depression risk of the invention
Sample is peripheral blood.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
Hsa-miR-139-5p, hsa-miR-340-3p of survey, hsa-let-7a-3p, hsa-miR-517a-3p, hsa-miR-641,
hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、
hsa-miR-495-3p、hsa-miR-511-5p、hsa-miR-421、hsa-miR-361-5p、hsa-miR-1304-5p、hsa-
miR-30c-5p、hsa-miR-19a-3p、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let-7b-3p、hsa-
The expression of miR-204-5p, hsa-miR-494-3p, hsa-miR-32-5p, hsa-miR-96-5p increase, test individual
Depression risk increases.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
Hsa-miR-139-5p, hsa-miR-340-3p of survey, hsa-let-7a-3p, hsa-miR-517a-3p, hsa-miR-641,
hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、
The table of hsa-miR-495-3p, hsa-miR-511-5p, hsa-miR-421, hsa-miR-361-5p, hsa-miR-1304-5p
It is increased up to level, test individual depression risk increases.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
Hsa-miR-139-5p, hsa-miR-340-3p of survey, hsa-let-7a-3p, hsa-miR-517a-3p, hsa-miR-641,
Hsa-miR-331-5p, hsa-miR-519a-5p, hsa-miR-126-3p, hsa-miR-330-5p, hsa-miR-22-5p's
Expression increases, and test individual depression risk increases.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
Hsa-miR-4497, hsa-miR-100-5p of survey, hsa-miR-378c, hsa-miR-769-5p, hsa-miR-144-3p,
hsa-miR-206、hsa-miR-127-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-17-3p、hsa-miR-
The expression of 378d, hsa-miR-184, hsa-miR-3656, hsa-miR-1268a reduce, test individual depression illness
Risk increases.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
Hsa-miR-4497, hsa-miR-100-5p of survey, hsa-miR-378c, hsa-miR-769-5p, hsa-miR-144-3p,
The expression of hsa-miR-206, hsa-miR-127-5p, hsa-miR-4488, hsa-miR-7704, hsa-miR-17-3p
It reduces, test individual depression risk increases.
Specific embodiment according to the present invention in the detection system of assessment depression risk of the invention, is examined
The expression of hsa-miR-4497, hsa-miR-100-5p of survey reduce, and test individual depression risk increases.
The expression of possible technique detection microRNA any in this field can be used.
Specific embodiment according to the present invention, in the present invention, the examination of the expression of the detection microRNA
Agent material and/or instrument and equipment can be used in the technology of the expression of any feasible detection microRNA
Reagent material and/or instrument and equipment etc..
The detection system of assessment depression risk of the invention, can be virtual bench, as long as being able to achieve the inspection
Survey the function of unit and assessment unit.The detection unit can be including various detection reagent materials and/or inspection
Survey instrument and equipment etc.；The data analysis unit, which can be, any may be implemented to analyze the testing result of detection unit
It handles and obtains operation instrument, module or the virtual unit of depression risk assessment situation, such as can be preparatory incite somebody to action
Various possible testing results data drawing list corresponding with corresponding risk situation formulation, will test the testing result of unit
Depression risk evaluation result can be obtained by compareing the data drawing list.
Using technology of the invention, can pathogenesis to depression and the new targeted therapy means of research provide it is positive
It helps.
Detailed description of the invention
Fig. 1 is the map for the particle diameter distribution that Zetaview detects the excretion body extracted in the embodiment of the present invention 1.
Fig. 2 is the MA-plot figure of data difference analysis in the embodiment of the present invention 2.In figure, X-axis is the read after standardization
Count value, Y-axis are the fold differences logarithm of starting depressive patient group and healthy control group, represent and lower less than 0, were greater than for 0 generation
Table up-regulation.Each point represents a miRNA in figure, and red dot is significant difference miRNA.
Fig. 3 A is the ROC curve figure of test set classification results of the present invention, and AUC index about 96.64%, figure Green region is
95% confidence interval.Fig. 3 B is the prediction probability box traction substation that training set sample belongs to depression group.Fig. 3 C is training set sample
The prediction probability scatter plot for belonging to depression group sorts X-axis from small to large.
Specific embodiment
In order to which technical characteristic of the invention, purpose and beneficial effect are more clearly understood, now to skill of the invention
Art scheme carries out described further below, but should not be understood as that limiting the scope of the invention.
Embodiment 1
Subject is depression division patient 33 that third the People's Hospital in Foshan City's is accepted for medical treatment, and recruits 46 ages and gender
Matched healthy volunteer is as control.All doctors for participating in diagnostic work all have the psychiatric department qualifications of a licensed doctor and have 10
Year or more psychiatric department working experience, skillfully check table using SCID-1, it is skilled to grasp ICD-10 and DSM-V diagnostic criteria, adopt
The spiritual pathological state of patient is commented with Hamilton depressive scale (HAMD) and Montgomery Depression Scale (MADRS)
Estimate, working specification is unified, and consistency detection reaches requirement (Kappa=0.68~0.82), excludes the depression with complication and suffers from
Person.All participants give Written informed consent before being included in research.Research approach is by the Foshan City third people
Hospital Ethical Committee's approval.
1. excretion body extracts:
About 4ml peripheral blood is collected from every subject, and condenses it at room temperature 1 hour, then by sample 3000
10 minutes are centrifuged under × g to obtain serum.Then serum deposited in -80 DEG C of low temperature refrigerators or directly analysis.
It is filtered using 0.22um filter membrane, filtrate is subjected to 10000G and is centrifuged 1 hour, carried out using 30kd super filter tube dense
Excretion body suspension is cleaned in contracting ultrafiltration, and the 1st 110000g of 20mlPBS is added and is centrifuged 70min, goes supernatant to stay 5mL tube bottom liquid, is resuspended
And gently blow and beat tube bottom liquid；2nd time 110000g is centrifuged 70min, and visible tube bottom pale yellow precipitate, goes supernatant to remain 1mL after centrifugation
Tube bottom liquid is resuspended with PBS and complements to centrifuge tube prescribed volume；3rd time 110000g is centrifuged 70min, carefully removes supernatant, will receive
The excretion body collected is transferred in the Eppendorf pipe of 1.5mL, is saved backup in -80 DEG C of refrigerators.
2. the identification of excretion body:
Nano particle tracer analysis instrument detects excretion body partial size: the excretion body of collection, which is diluted to granule density with PBS, is
106/ mL is analyzed with 1mL syringe injection nano particle trace analysis instrument, and is saved analysis data.
Analyzer operating parameter and result are shown in Figure 1, and display particle size meets excretion body characteristic feature, and concentration
For 2.8E+13/mL.
Embodiment 2
After the sample to embodiment 1 carries out the extraction of excretion body and Total RNAs extraction, sample is subjected to full microRNA sequencing
Analysis, and gene expression abundance is for statistical analysis, and data are indicated with mean+SD.It is counted using double tail T- inspection
Analysis, p < 0.05 is considered to have statistical significance.
1. screening significant difference miRNA
In the present embodiment, there is the expression quantity of 79 samples, wherein 46 normal healthy controls, 33 depressive patients.The present embodiment
In, the low expression miRNA of mean value < 10 of the TPM in all samples is filtered out, totally 351 miRNA enter variance analysis.
In the present embodiment, variance analysis is done using DESeq2, defines Q value Qvalue (adjust-p)≤0.05 and difference
The miRNA of multiple >=2 is significant difference miRNA, finally screens to obtain 38 significant difference miRNA (table 1), MA-plot is shown in
Fig. 2.
1. first batch data significant difference miRNA of table
In Fig. 2, X-axis is the read count value after standardization, and Y-axis is the difference that starting essence divides patient group and healthy control group
Different multiple logarithm is represented less than 0 and is lowered, and is greater than 0 and is represented up-regulation.Each point represents a miRNA in figure, and red dot is significance difference
Different miRNA.
Embodiment 3
Random forests algorithm model training is carried out to 33 depression samples and 46 check samples, filters out miRNA mark
Will object.
Analyze result:
1. screening miRNA marker
In the original miRNA of training set, after filtering out low expression miRNA (in mean value TPM < 10 in whole samples),
Remaining miRNA is made of random forests algorithm and is classified, it is proposed that classifier.Table 2 is that classifier screens 25 miRNA markers
With its expression quantity situation.The probability distribution that its ROC curve and each sample are judged as depression is shown in Fig. 3 A, Fig. 3 B and Fig. 3 C.
Simultaneously using probability0.3464 as cutoff, take statistics to true and false positive rate, true and false negative rate.
The miRNA marker that table 2. is filtered out from training set
True positive rate (sensibility): 32/33=96.97%；
True negative rate (specificity): 39/46=84.78%；
False positive rate (misdiagnosis rate): 7/46=15.22%；
False negative rate (rate of missed diagnosis): 1/33=3.03%.
Conclusion:
Screening miRNA marker is gone using data as training set, comparatively ideal ROC curve figure can be obtained, AUC index is up to
96.64%, the sensibility and specificity itself come out is also higher, and respectively 96.97% and 84.78%.Result above
Show that the excretion body miRNA that the present invention screens can be used as the biomarker for diagnosing depressive patients.
Claims (10)
- Application of one of the microRNA below 1. or a variety of as the biomarker of diagnosis depression:hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、 hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、 hsa-miR-4497、hsa-miR-495-3p、hsa-miR-100-5p、hsa-miR-511-5p、hsa-miR-421、hsa- miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-378c、hsa-miR-769-5p、hsa- miR-19a-3p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let- 7b-3p、hsa-miR-127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、 hsa-miR-32-5p、hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR- 3656、hsa-miR-1268a。
- 2. the reagent material and/or instrument and equipment that detect microRNA level in the sample from test individual are being prepared for examining Application in the detection system of disconnected depression risk, the microRNA includes one of following microRNA or more Kind:hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、 hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、 hsa-miR-4497、hsa-miR-495-3p、hsa-miR-100-5p、hsa-miR-511-5p、hsa-miR-421、hsa- miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-378c、hsa-miR-769-5p、hsa- miR-19a-3p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let- 7b-3p、hsa-miR-127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、 hsa-miR-32-5p、hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR- 3656、hsa-miR-1268a。
- 3. application according to claim 2, wherein microRNA level includes peripheral blood expression or serum expression water It is flat.
- 4. application according to claim 2, wherein hsa-miR-139-5p, hsa-miR-340-3p, hsa-let-7a- 3p、hsa-miR-517a-3p、hsa-miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、 hsa-miR-330-5p、hsa-miR-22-5p、hsa-miR-495-3p、hsa-miR-511-5p、hsa-miR-421、hsa- miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-19a-3p、hsa-miR-335-3p、hsa- miR-625-3p、hsa-let-7b-3p、hsa-miR-204-5p、hsa-miR-494-3p、hsa-miR-32-5p、hsa-miR- The expression of 96-5p increases, and test individual depression risk increases；Preferably, hsa-miR-139-5p, hsa-miR-340-3p, hsa-let-7a-3p, hsa-miR-517a-3p, hsa- miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR- 22-5p、hsa-miR-495-3p、hsa-miR-511-5p、hsa-miR-421、hsa-miR-361-5p、hsa-miR-1304- The expression of 5p increases, and test individual depression risk increases；Preferably, hsa-miR-139-5p, hsa-miR-340-3p, hsa-let-7a-3p, hsa-miR-517a-3p, hsa- miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR- The expression of 22-5p increases, and test individual depression risk increases.
- 5. application according to claim 2, wherein hsa-miR-4497, hsa-miR-100-5p, hsa-miR-378c, hsa-miR-769-5p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-127-5p、hsa-miR-4488、hsa- MiR-7704, hsa-miR-17-3p, hsa-miR-378d, hsa-miR-184, hsa-miR-3656, hsa-miR-1268a's Expression reduces, and test individual depression risk increases；Preferably, hsa-miR-4497, hsa-miR-100-5p, hsa-miR-378c, hsa-miR-769-5p, hsa-miR- The table of 144-3p, hsa-miR-206, hsa-miR-127-5p, hsa-miR-4488, hsa-miR-7704, hsa-miR-17-3p It is reduced up to level, test individual depression risk increases；Preferably, the expression of hsa-miR-4497, hsa-miR-100-5p reduce, test individual depression risk liter It is high.
- 6. a kind of detection system for assessing depression risk comprising: with next in sample of the detection from test individual The reagent material and/or instrument and equipment of kind or a variety of microRNA level:hsa-miR-139-5p、hsa-miR-340-3p、hsa-let-7a-3p、hsa-miR-517a-3p、hsa-miR-641、 hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR-22-5p、 hsa-miR-4497、hsa-miR-100-5p、hsa-miR-378c、hsa-miR-769-5p、hsa-miR-19a-3p、hsa- miR-144-3p、hsa-miR-206、hsa-miR-335-3p、hsa-miR-625-3p、hsa-let-7b-3p、hsa-miR- 127-5p、hsa-miR-204-5p、hsa-miR-4488、hsa-miR-7704、hsa-miR-494-3p、hsa-miR-32-5p、 hsa-miR-17-3p、hsa-miR-96-5p、hsa-miR-378d、hsa-miR-184、hsa-miR-3656、hsa-miR- 1268a。
- 7. detection system according to claim 6 comprising:Detection unit, the detection unit include detecting the reagent material and/or instrument and equipment of the microRNA level；Analytical unit, the analytical unit for analyzing the testing result of detection unit, suffer from by assessment test individual depression Sick risk.
- 8. detection system according to claim 6, wherein the sample is peripheral blood.
- 9. detection system according to claim 6, wherein hsa-miR-139-5p, hsa-miR-340-3p, hsa-let- 7a-3p、hsa-miR-517a-3p、hsa-miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126- 3p、hsa-miR-330-5p、hsa-miR-22-5p、hsa-miR-495-3p、hsa-miR-511-5p、hsa-miR-421、 hsa-miR-361-5p、hsa-miR-1304-5p、hsa-miR-30c-5p、hsa-miR-19a-3p、hsa-miR-335-3p、 hsa-miR-625-3p、hsa-let-7b-3p、hsa-miR-204-5p、hsa-miR-494-3p、hsa-miR-32-5p、hsa- The expression of miR-96-5p increases, and test individual depression risk increases；Preferably, hsa-miR-139-5p, hsa-miR-340-3p, hsa-let-7a-3p, hsa-miR-517a-3p, hsa- miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR- 22-5p、hsa-miR-495-3p、hsa-miR-511-5p、hsa-miR-421、hsa-miR-361-5p、hsa-miR-1304- The expression of 5p increases, and test individual depression risk increases；Preferably, hsa-miR-139-5p, hsa-miR-340-3p, hsa-let-7a-3p, hsa-miR-517a-3p, hsa- miR-641、hsa-miR-331-5p、hsa-miR-519a-5p、hsa-miR-126-3p、hsa-miR-330-5p、hsa-miR- The expression of 22-5p increases, and test individual depression risk increases.
- 10. detection system according to claim 6, wherein hsa-miR-4497, hsa-miR-100-5p, hsa-miR- 378c、hsa-miR-769-5p、hsa-miR-144-3p、hsa-miR-206、hsa-miR-127-5p、hsa-miR-4488、 hsa-miR-7704、hsa-miR-17-3p、hsa-miR-378d、hsa-miR-184、hsa-miR-3656、hsa-miR- The expression of 1268a reduces, and test individual depression risk increases；Preferably, hsa-miR-4497, hsa-miR-100-5p, hsa-miR-378c, hsa-miR-769-5p, hsa-miR- The table of 144-3p, hsa-miR-206, hsa-miR-127-5p, hsa-miR-4488, hsa-miR-7704, hsa-miR-17-3p It is reduced up to level, test individual depression risk increases；Preferably, the expression of hsa-miR-4497, hsa-miR-100-5p reduce, test individual depression risk liter It is high.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910567173.4A CN110272990A (en) | 2019-06-27 | 2019-06-27 | Excretion body microRNA is as depression marker and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910567173.4A CN110272990A (en) | 2019-06-27 | 2019-06-27 | Excretion body microRNA is as depression marker and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110272990A true CN110272990A (en) | 2019-09-24 |
Family
ID=67963459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910567173.4A Pending CN110272990A (en) | 2019-06-27 | 2019-06-27 | Excretion body microRNA is as depression marker and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110272990A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020224620A1 (en) * | 2019-05-07 | 2020-11-12 | 中央民族大学 | Exosome microrna as schizophrenia marker and use thereof |
| CN112094808A (en) * | 2020-09-16 | 2020-12-18 | 中山大学中山眼科中心 | MiR-204-containing exosome and preparation method and application thereof |
| CN112386679A (en) * | 2020-11-18 | 2021-02-23 | 徐州医科大学 | Application of sigma-1 receptor-entrapped exosome in preparation of antidepressant drugs |
| CN113134011A (en) * | 2021-05-24 | 2021-07-20 | 中国人民解放军军事科学院军事医学研究院 | Application of miR-129 in preparation of product for treating depression |
| WO2021263142A1 (en) * | 2020-06-26 | 2021-12-30 | Unm Rainforest Innovations | Signature mirna to predict neonatal opioid withdrawal syndrome (nows) |
| CN114657240A (en) * | 2020-12-03 | 2022-06-24 | 南京大学 | Application of miR-199a-3p in sperms in preparation of depression detection products and anti-depression drugs |
| JP7436004B2 (en) | 2020-01-20 | 2024-02-21 | 学校法人産業医科大学 | Diagnostic aid method and diagnostic kit for depression |
-
2019
- 2019-06-27 CN CN201910567173.4A patent/CN110272990A/en active Pending
Non-Patent Citations (5)
| Title |
|---|
| JAHANSHIR TAVAKOLIZADEH等: "MicroRNAs and exosomes in depression: Potential diagnostic biomarkers", 《J CELL BIOCHEM.》 * |
| YOGESH DWIVEDI: "Emerging role of microRNAs in major depressive disorder: diagnosis and therapeutic implications", 《DIALOGUES CLIN NEUROSCI.》 * |
| YOGESH DWIVEDI: "Pathogenetic and therapeutic application of microRNAs in major depressive disorder", 《PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY》 * |
| YUNQIANG WAN等: "Identification of Differential MicroRNAs in Cerebrospinal Fluid and Serum of Patients with Major Depressive Disorder", 《PLOS ONE》 * |
| 郭天蔚: "大学生抑郁状态早期筛查、干预及循环microRNA测序研究", 《中国优秀博硕士学位论文全文数据库（博士） 医药卫生科技辑》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020224620A1 (en) * | 2019-05-07 | 2020-11-12 | 中央民族大学 | Exosome microrna as schizophrenia marker and use thereof |
| JP7436004B2 (en) | 2020-01-20 | 2024-02-21 | 学校法人産業医科大学 | Diagnostic aid method and diagnostic kit for depression |
| WO2021263142A1 (en) * | 2020-06-26 | 2021-12-30 | Unm Rainforest Innovations | Signature mirna to predict neonatal opioid withdrawal syndrome (nows) |
| CN112094808A (en) * | 2020-09-16 | 2020-12-18 | 中山大学中山眼科中心 | MiR-204-containing exosome and preparation method and application thereof |
| CN112386679A (en) * | 2020-11-18 | 2021-02-23 | 徐州医科大学 | Application of sigma-1 receptor-entrapped exosome in preparation of antidepressant drugs |
| CN112386679B (en) * | 2020-11-18 | 2023-05-30 | 徐州医科大学 | Application of exosomes encapsulating sigma-1 receptor in preparation of antidepressant drugs |
| CN114657240A (en) * | 2020-12-03 | 2022-06-24 | 南京大学 | Application of miR-199a-3p in sperms in preparation of depression detection products and anti-depression drugs |
| CN114657240B (en) * | 2020-12-03 | 2024-04-02 | 南京大学 | Application of miR-199a-3p in sperms in preparation of depression detection products and antidepressant drugs |
| CN113134011A (en) * | 2021-05-24 | 2021-07-20 | 中国人民解放军军事科学院军事医学研究院 | Application of miR-129 in preparation of product for treating depression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110272990A (en) | Excretion body microRNA is as depression marker and its application | |
| CN106529202A (en) | Intelligent auditing system and method for medical specimen testing | |
| CN104450901B (en) | The nucleic acid markers of quick diagnosis mucocutaneous lymphnode syndrome and test kit thereof | |
| CN107849610A (en) | Early stage Alzheimer disease or mild cognitive impairment diagnostic method | |
| CN109777874A (en) | It is a kind of suitable for ductal adenocarcinoma of pancreas diagnosis and Index for diagnosis blood plasma excretion body miRNA marker and application | |
| JP2011516046A5 (en) | ||
| CN104651513B (en) | A kind of detection method of gout serum miRNAs biomarkers and its expression quantity | |
| CN106755522A (en) | A kind of kit for the detection of juvenile form osteoporosis | |
| JP2008253258A (en) | Method for examining depression | |
| CN105603101A (en) | Application of system for detecting expression quantity of eight miRNAs in preparation of product for diagnosing or assisting in diagnosing hepatocellular carcinoma | |
| CN112852916A (en) | Marker combination for intestinal microecology, auxiliary diagnosis model and application of marker combination | |
| CN103293250B (en) | Diabetic nephropathy diagnostic kit and application thereof | |
| CN110379459A (en) | A kind of method and system being associated with discovery molecular marker with gene function based on transcript profile dynamic change of temporal series | |
| CN108949979A (en) | A method of judging that Lung neoplasm is good pernicious by blood sample | |
| CN108508211A (en) | Starting non-medication schizophrenic patients blood serum designated object FGF9 and its application | |
| CN108070656A (en) | Lung cancer marker and its application | |
| CN110396538A (en) | Migraine biomarker and application thereof | |
| CN108220416A (en) | A kind of kit and its application for being used to detect deficiency of Yin excessive internal heat constitution serum specificity miRNA | |
| CN108588218A (en) | A kind of minimally invasive detection kit of serum miRNA combination | |
| CN108531569A (en) | The gene marker screened for obsessive-compulsive disorder and schizophrenia, depression and its application | |
| CN110205377A (en) | The assessment in advance of Kawasaki disease risk | |
| CN110511995A (en) | One group of tuberculosis marker and its application | |
| CN105349643B (en) | The method and microRNAs markers that serotonin changes after prediction sleep deprivation | |
| CN109207585A (en) | Immune thrombocytopenia lncRNA marker and kit and application | |
| CN110129445A (en) | One kind cerebrospinal fluid excretion body miRNA marker relevant to glioma and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190924 |
|
| RJ01 | Rejection of invention patent application after publication |